Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 1
1994 6
1995 12
1996 23
1997 35
1998 45
1999 69
2000 62
2001 59
2002 63
2003 69
2004 72
2005 92
2006 95
2007 106
2008 107
2009 114
2010 146
2011 141
2012 134
2013 136
2014 136
2015 158
2016 164
2017 141
2018 152
2019 152
2020 158
2021 176
2022 161
2023 119
2024 41

Text availability

Article attribute

Article type

Publication date

Search Results

2,775 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Fanconi anemia, complementation group S"
Page 1
Triple-negative breast cancer.
Foulkes WD, Smith IE, Reis-Filho JS. Foulkes WD, et al. N Engl J Med. 2010 Nov 11;363(20):1938-48. doi: 10.1056/NEJMra1001389. N Engl J Med. 2010. PMID: 21067385 Free article. Review.
Biomarker-Guided Development of DNA Repair Inhibitors.
Cleary JM, Aguirre AJ, Shapiro GI, D'Andrea AD. Cleary JM, et al. Mol Cell. 2020 Jun 18;78(6):1070-1085. doi: 10.1016/j.molcel.2020.04.035. Epub 2020 May 26. Mol Cell. 2020. PMID: 32459988 Free PMC article. Review.
For example, defects in homologous recombination (HR) repair arise in cancer cells through inherited or acquired mutations in BRCA1, BRCA2, or other genes in the Fanconi anemia/BRCA pathway, and these tumors have been shown to be particularly sensitive to inhibitors …
For example, defects in homologous recombination (HR) repair arise in cancer cells through inherited or acquired mutations in BRCA1, …
BRCA-CRisk: A Contralateral Breast Cancer Risk Prediction Model for BRCA Carriers.
Sun J, Chu F, Pan J, Zhang Y, Yao L, Chen J, Hu L, Zhang J, Xu Y, Wang X, Cao W, Xie Y. Sun J, et al. J Clin Oncol. 2023 Feb 10;41(5):991-999. doi: 10.1200/JCO.22.00833. Epub 2022 Dec 8. J Clin Oncol. 2023. PMID: 36480783
PURPOSE: The absolute cumulative risk of contralateral breast cancer (CBC) for patients with BRCA1/2 variants is unknown. The purpose of this study was to develop a CBC risk prediction model for assessing CBC risk for BRCA1/2 carriers. METHODS: The primary co …
PURPOSE: The absolute cumulative risk of contralateral breast cancer (CBC) for patients with BRCA1/2 variants is unknown. The purpose …
OlympiAD extended follow-up for overall survival and safety: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer.
Robson ME, Im SA, Senkus E, Xu B, Domchek SM, Masuda N, Delaloge S, Tung N, Armstrong A, Dymond M, Fielding A, Allen A, Conte P. Robson ME, et al. Eur J Cancer. 2023 May;184:39-47. doi: 10.1016/j.ejca.2023.01.031. Epub 2023 Feb 14. Eur J Cancer. 2023. PMID: 36893711 Free PMC article. Clinical Trial.
Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2.
King MC, Marks JH, Mandell JB; New York Breast Cancer Study Group. King MC, et al. Science. 2003 Oct 24;302(5645):643-6. doi: 10.1126/science.1088759. Science. 2003. PMID: 14576434
Risks of breast and ovarian cancer were determined for Ashkenazi Jewish women with inherited mutations in the tumor suppressor genes BRCA1 and BRCA2. We selected 1008 index cases, regardless of family history of cancer, and carried out molecular analysis across enti …
Risks of breast and ovarian cancer were determined for Ashkenazi Jewish women with inherited mutations in the tumor suppressor genes …
Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies.
Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, Loman N, Olsson H, Johannsson O, Borg A, Pasini B, Radice P, Manoukian S, Eccles DM, Tang N, Olah E, Anton-Culver H, Warner E, Lubinski J, Gronwald J, Gorski B, Tulinius H, Thorlacius S, Eerola H, Nevanlinna H, Syrjäkoski K, Kallioniemi OP, Thompson D, Evans C, Peto J, Lalloo F, Evans DG, Easton DF. Antoniou A, et al. Am J Hum Genet. 2003 May;72(5):1117-30. doi: 10.1086/375033. Epub 2003 Apr 3. Am J Hum Genet. 2003. PMID: 12677558 Free PMC article.
Relative risks of breast cancer declined significantly with age for BRCA1-mutation carriers (P trend.0012) but not for BRCA2-mutation carriers. ...The variation in risk by age at diagnosis of index case is consistent with the effects of other genes modifying cancer …
Relative risks of breast cancer declined significantly with age for BRCA1-mutation carriers (P trend.0012) but not for BRCA2-mutation …
Whole genome sequencing of breast cancer.
Rossing M, Sørensen CS, Ejlertsen B, Nielsen FC. Rossing M, et al. APMIS. 2019 May;127(5):303-315. doi: 10.1111/apm.12920. Epub 2019 Jan 28. APMIS. 2019. PMID: 30689231 Free PMC article. Review.
Large-scale sequencing data unravel novel somatic and potential targetable mutations as well as allowing the identification of new candidate genes predisposing for familial breast cancer. So far, around 15% of all breast cancer patients are genetically predisposed with mos …
Large-scale sequencing data unravel novel somatic and potential targetable mutations as well as allowing the identification of new candidate …
Hereditary breast cancer in the Han Chinese population.
Cao W, Wang X, Li JC. Cao W, et al. J Epidemiol. 2013;23(2):75-84. doi: 10.2188/jea.je20120043. Epub 2013 Jan 12. J Epidemiol. 2013. PMID: 23318652 Free PMC article. Review.
BRCA1 and BRCA2 are the 2 most important susceptibility genes. They have a relatively low mutation rate, and the most frequent sites of mutation are in exon 11. ...At present, the mutation spectrum for these susceptibility genes is not well understood in the …
BRCA1 and BRCA2 are the 2 most important susceptibility genes. They have a relatively low mutation rate, and the most frequent …
Ovarian cancer as a genetic disease.
Lech A, Daneva T, Pashova S, Gagov H, Crayton R, Kukwa W, Czarnecka AM, Szczylik C. Lech A, et al. Front Biosci (Landmark Ed). 2013 Jan 1;18(2):543-63. doi: 10.2741/4119. Front Biosci (Landmark Ed). 2013. PMID: 23276941 Free article. Review.
Those factors considerably contribute to accurate diagnostics, treatment and prognosis in ovarian cancer....
Those factors considerably contribute to accurate diagnostics, treatment and prognosis in ovarian cancer....
Prophylactic mastectomy.
Zakaria S, Degnim AC. Zakaria S, et al. Surg Clin North Am. 2007 Apr;87(2):317-31, viii. doi: 10.1016/j.suc.2007.01.009. Surg Clin North Am. 2007. PMID: 17498529 Review.
2,775 results